Kubo M - Search Results

1

Enhanced activated T cell subsets in prostate cancer patients receiving iodine-125 low-dose-rate prostate brachytherapy.

Kubo M, Satoh T, Ishiyama H, Tabata KI, Tsumura H, Komori S, Iwamura M, Baba S, Hayakawa K, Kawamura T, Obata F. Kubo M, et al. Oncol Rep. 2018 Jan;39(1):417-424. doi: 10.3892/or.2017.6095. Epub 2017 Nov 13. Oncol Rep. 2018. PMID: 29138841 Clinical Trial.

2

Binding properties of human immunodeficiency virus type-2 (HIV-2) RNA corresponding to the packaging signal to its nucleocapsid protein.

Tsukahara T, Komatsu H, Kubo M, Obata F, Tozawa H. Tsukahara T, et al. Among authors: kubo m. Biochem Mol Biol Int. 1996 Sep;40(1):33-42. doi: 10.1080/15216549600201502. Biochem Mol Biol Int. 1996. PMID: 8886267

3

[Educational program in the Medical Science Course, Kitasato University School of Allied Health Sciences].

Kitasato H, Takahashi S, Ohbu M, Obata F, Ogawa Z, Sato Y, Hattori M, Saito-Taki T, Hara K, Okano T, Kubo M, Maruyama H, Tsuchiya B, Okazaki T, Ishii N, Nishimura Y, Takada N, Abe M, Hachimura K, Tanigawa K, Katagiri M. Kitasato H, et al. Among authors: kubo m. Rinsho Byori. 2008 Jul;56(7):606-11. Rinsho Byori. 2008. PMID: 18709993 Japanese.

4

Prevention of intracellular degradation of I2020T mutant LRRK2 restores its protectivity against apoptosis.

Ohta E, Kubo M, Obata F. Ohta E, et al. Among authors: kubo m. Biochem Biophys Res Commun. 2010 Jan 1;391(1):242-7. doi: 10.1016/j.bbrc.2009.11.043. Epub 2009 Nov 11. Biochem Biophys Res Commun. 2010. PMID: 19912990

5

Age-dependent and cell-population-restricted LRRK2 expression in normal mouse spleen.

Maekawa T, Kubo M, Yokoyama I, Ohta E, Obata F. Maekawa T, et al. Among authors: kubo m. Biochem Biophys Res Commun. 2010 Feb 12;392(3):431-5. doi: 10.1016/j.bbrc.2010.01.041. Epub 2010 Jan 15. Biochem Biophys Res Commun. 2010. PMID: 20079710

6

LRRK2 is expressed in B-2 but not in B-1 B cells, and downregulated by cellular activation.

Kubo M, Kamiya Y, Nagashima R, Maekawa T, Eshima K, Azuma S, Ohta E, Obata F. Kubo M, et al. J Neuroimmunol. 2010 Dec 15;229(1-2):123-8. doi: 10.1016/j.jneuroim.2010.07.021. Epub 2010 Aug 21. J Neuroimmunol. 2010. PMID: 20728949

7

LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations.

Ohta E, Kawakami F, Kubo M, Obata F. Ohta E, et al. Among authors: kubo m. FEBS Lett. 2011 Jul 21;585(14):2165-70. doi: 10.1016/j.febslet.2011.05.044. Epub 2011 Jun 2. FEBS Lett. 2011. PMID: 21658387 Free article.

8

Correlation of PU.1 and signal regulatory protein α1 expression in PU.1 transgenic K562 cells.

Iseki Y, Nakahara M, Kubo M, Obata F, Harigae H, Takahashi S. Iseki Y, et al. Among authors: kubo m. Int J Mol Med. 2012 Feb;29(2):319-23. doi: 10.3892/ijmm.2011.827. Epub 2011 Nov 7. Int J Mol Med. 2012. PMID: 22075620

9

Dominant-negative effects of LRRK2 heterodimers: a possible mechanism of neurodegeneration in Parkinson's disease caused by LRRK2 I2020T mutation.

Ohta E, Kawakami F, Kubo M, Obata F. Ohta E, et al. Among authors: kubo m. Biochem Biophys Res Commun. 2013 Jan 11;430(2):560-6. doi: 10.1016/j.bbrc.2012.11.113. Epub 2012 Dec 7. Biochem Biophys Res Commun. 2013. PMID: 23220480

10

Allo-antigen stimulated CD8+ T-cells suppress NF-κB and Ets-1 DNA binding activity, and inhibit phosphorylated NF-κB p65 nuclear localization in CD4+ T-cells.

Nagashima R, Kawakami F, Takahashi S, Obata F, Kubo M. Nagashima R, et al. Among authors: kubo m. Viral Immunol. 2014 Aug;27(6):305-15. doi: 10.1089/vim.2013.0113. Epub 2014 May 20. Viral Immunol. 2014. PMID: 24844121 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,771 results

Search Page

Filters